We next tested the activity of OST-01 in combination with venetoclax (VEN), a selective BCL-2 inhibitor broadly used in combination with hypomethylating agents or other chemotherapeutics in AML patients [13], in CD34 + CD38- AML blasts. This evidence concerns the gene CD38 and acute myeloid leukemia.